Jesús Fernández-Sainz

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Single Molecule

Molecular Dynamics Simulations

Electron Transfer

Human Serum Albumin

Top Venues

Molecular pharmaceutics

This page only lists publications with an associated author ORCID identifier.

Publications

Jesús Fernández-Sainz, Pedro J Pacheco-Liñán, Consuelo Ripoll, Joaquín González-Fuentes, José Albaladejo, Iván Bravo, Andrés Garzón-Ruiz
Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications. Molecular pharmaceutics 20 (3) (2023)
Jesús Fernández-Sainz, Pedro J Pacheco-Liñán, Consuelo Ripoll, Joaquín González-Fuentes, José Albaladejo, Iván Bravo, Andrés Garzón-Ruiz
Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications. Molecular pharmaceutics 20 (3) (2023)
Jesús Fernández-Sainz, Pedro J Pacheco-Liñán, Consuelo Ripoll, Joaquín González-Fuentes, José Albaladejo, Iván Bravo, Andrés Garzón-Ruiz
Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications. Molecular pharmaceutics 20 (3) (2023)
Jesús Fernández-Sainz, Pedro J Pacheco-Liñán, Consuelo Ripoll, Joaquín González-Fuentes, José Albaladejo, Iván Bravo, Andrés Garzón-Ruiz
Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications. Molecular pharmaceutics 20 (3) (2023)
Jesús Fernández-Sainz, Pedro J Pacheco-Liñán, Consuelo Ripoll, Joaquín González-Fuentes, José Albaladejo, Iván Bravo, Andrés Garzón-Ruiz
Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications. Molecular pharmaceutics (2023)
Jesús Fernández-Sainz, Pedro J Pacheco-Liñán, Consuelo Ripoll, Joaquín González-Fuentes, José Albaladejo, Iván Bravo, Andrés Garzón-Ruiz
Unusually High Affinity of the PLK Inhibitors RO3280 and GSK461364 to HSA and Its Possible Pharmacokinetic Implications. Molecular pharmaceutics 20 (3) (2023)